

Global Companion Animal Drugs Market: By Product Type (Antimicrobials, Ectoparasiticides, Endoparasitides, Endectoparasiticides, Anti-inflammatory Drugs, Anti-Obesity Drugs, Behavioral Products, Biologic Drugs and Others), By Animal Type (Feline, canine, and Equine), By Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals, Veterinary Clinics, and E-Commerce), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G528944CB14EN.html>

Date: September 2017

Pages: 190

Price: US\$ 4,400.00 (Single User License)

ID: G528944CB14EN

Abstracts

Global Companion Animal Drugs Market Report Description:

Companion animal drugs market report gives comprehensive outlook on companion animal drugs market across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on companion animal drugs market gives historical, current, and future market sizes (US\$ Mn) on the basis of product type, animal type, route of administration, distribution channel, and geographic regions. This report studies companion animal drugs market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, companion animal drugs market report includes animal

demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed companion animal drugs market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the companion animal drugs market report include suppliers, manufacturers, marketers, policy makers, and veterinary healthcare service providers engaged in manufacturing and supply of companion animal drug products.

Global Companion Animal Drugs Market:

Global companion animal drugs market estimated to be valued US\$ XX Mn in 2017 and poised to grow at CAGR of 5.6% over 2017-2023. Market for companion animal drugs projected to reach US\$ XX Mn by 2023 owing to rising human and companion animals bondage by means of adoption across the globe.

Rising Pet companionship to the human beings expected to drive the companion animal drugs market over the forecast period

Companion animals have been trusted for their companionship to the human throughout the history and keeping the companion animals healthy is a top priority for caregivers everywhere in the world, which is expected to drive the companion animal market over six years forecast period. Moreover, several studies on human and companion animals' interactions showed that association with companion animals results in positive health benefits. Therefore, it is essential to veterinarians and caregivers to give utmost attention to companion animal health as companion animals are primary source of zoonotic diseases spread to humans and vice versa, this is expected to create significant market demand for companion animal drugs over the forecast period.

Increasing per pet expenditure in recent times expected to drive market revenue growth

Several respondents and pet owners revealed that pet expenditure is increasingly becoming integral part of their monthly expenditure and companion animals are part of several families across the developed and developing economies. Moreover, rising interactions between pets and human beings prompting the care givers and pet owners to adopt better healthcare services to the companion animals this is projected to drive market revenue growth over the forecast period.

North America accounted for larger market revenue share in global companion animal

drugs market

U.S. market dominated the companion animal drugs market with largest market share in North America market with moderate growth rate. Europe companion animal drugs market holds significant share in global companion animal drugs market and projected to grow at significant growth over the forecast period.

COMPETITION ASSESSMENT

Key players profiles in the global Companion Animal Drugs market include:

Bayer AG (Germany)

Boehringer Ingelheim GmbH (Germany)

Ceva Santé Animale (France)

Eli Lilly and Company (U.S)

Hester biosciences (India)

Merck & Co., Inc. (U.S)

Vétoquinol S.A. (France)

Virbac S.A. (France)

Zoetis Inc. (U.S)

Players in the companion animal drugs market are launching the products in the market to garner larger market share. For instance, in July 2016, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, received U.S. Food and Drug Administration's approval for BRAVECTO (fluralaner topical solution) a topical treatment for fleas and ticks for both cats and dogs.

KEY FINDINGS OF THE REPORT:

Companion animal drugs market expanding at 5.6%

CAGR over 2017 to 2023 to reach market value of US\$ XX Mn by 2023 owing to increased adoption pet animals and rising zoonotic diseases

Based on product type paraciticides accounted for larger market revenue share in 2016 and projected gain larger market revenue share over the forecast period

Veterinary clinics distribution channel is the prime source for companion drugs across the globe and expected to remain attractive over the forecast period

Players focusing on launching products to retain market position in global companion animal drugs market

KEY FEATURES OF THE REPORT:

The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)

The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies

The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

The report tracks recent innovations, key developments and startup's details that are actively working in the market

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Product Type

Antimicrobials

Ectoparasiticides

Endoparasitides

Endectoparasiticides

Anti-inflammatory Drugs

Anti-Obesity Drugs

Behavioral Products

Biologic Drugs

Others

By Animal Type

Feline

Canine

Equine

By Route of Administration

Oral

Parenteral

Topical

Others

Distribution Channel

Veterinary Pharmacies

Veterinary Hospitals

Veterinary Clinics

E-Commerce

Geography

North America

U.S

Canada

Europe

Germany

France

U.K

Italy

Spain

Russia

Poland

Rest of Europe

Asia-Pacific

Japan

China

India

Australia & New Zealand

ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)

South Korea

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Argentina

Venezuela

Rest of Latin America

Middle East and Africa (MEA)

Gulf Cooperation Council (GCC) Countries

Israel

South Africa

Rest of MEA

Contents

1. RESEARCH METHODOLOGY

- 1.1. Secondary and Primary research
 - 1.1.1. Secondary Sources
 - 1.1.2. Primary Sources
- 1.2. Market Revenue Estimation Methodology
- 1.3. Key Assumptions
- 1.4. Acronyms

2. SCOPE OF STUDY

- 2.1. Market Definition
- 2.2. Objective of the Research
- 2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL COMPANION ANIMAL DRUGS MARKET DYNAMICS

- 4.1. Drivers
 - 4.1.1. Economic Drivers
 - 4.1.2. Demand Side Drivers
 - 4.1.3. Supply Side Drivers
- 4.2. Restraints
- 4.3. Opportunities/Unmet Needs of the Market
- 4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

- 5.1. Competition analysis
- 5.2. Regulatory landscape
- 5.3. PESTLE analysis
- 5.4. Porter's analysis

6. GLOBAL COMPANION ANIMAL DRUGS MARKET ANALYSIS, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Antimicrobials

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.2. Ectoparasiticides

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.3. Endoparasitides

6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.4. Endectoparasiticides

6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.5. Anti-Inflammatory Drugs

6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.6. Anti-Obesity Drugs

6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.7. Behavioral Products

6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.8. Biologic Drugs

6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

6.9. Others

6.9.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL COMPANION ANIMAL DRUGS MARKET ANALYSIS, BY ANIMAL TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Feline

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7.2. Canine

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7.3. Equine

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL COMPANION ANIMAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Oral

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8.2. Parenteral

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8.3. Topical

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8.4. Others

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL COMPANION ANIMAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Veterinary Pharmacies

9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.2. Veterinary Hospitals

9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.3. Veterinary Clinics

9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9.4. E-Commerce

9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)

9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. GLOBAL COMPANION ANIMAL DRUGS MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. North America Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 10.1.1.1. Antimicrobials
- 10.1.1.2. Ectoparasiticides
- 10.1.1.3. Endoparacitides
- 10.1.1.4. Endectoparaciticides
- 10.1.1.5. Anti-inflammatory Drugs
- 10.1.1.6. Anti-Obesity Drugs
- 10.1.1.7. Behavioral Products
- 10.1.1.8. Biologic Drugs
- 10.1.1.9. Others

10.1.2. Animal Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 10.1.2.1. Feline
- 10.1.2.2. Canine
- 10.1.2.3. Equine

10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 10.1.3.1. Veterinary Pharmacies
- 10.1.3.2. Veterinary Hospitals
- 10.1.3.3. Veterinary Clinics
- 10.1.3.4. E-Commerce

10.1.4. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 10.1.4.1. Oral
- 10.1.4.2. Parenteral
- 10.1.4.3. Topical
- 10.1.4.4. Others

10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 10.1.5.1. U.S
- 10.1.5.2. Canada

10.2. Europe Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

10.2.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

- 10.2.1.1. Drug Therapy
 - 10.2.1.1.1. Gemcitabine Combination Therapy
 - 10.2.1.1.2. 5-fluorouracil Combination Therapy

- 10.2.1.1.3. Capecitabine Combination Therapy
- 10.2.1.1.4. Gemcitabine Alone
- 10.2.1.2. Radiation Therapy
 - 10.2.1.2.1. Brachytherapy
 - 10.2.1.2.2. External Beam Radiation Product (EBRT)
- 10.2.1.3. Surgery
- 10.2.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
- 10.2.3. Intrahepatic Bile Duct Cancer
- 10.2.4. Extrahepatic Bile Duct Cancer
 - 10.2.4.1. Perihilar Bile Duct Cancer
 - 10.2.4.2. Distal Extrahepatic Bile Duct Cancer
- 10.2.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.2.5.1. Hospitals
 - 10.2.5.2. Pharmacies
 - 10.2.5.3. Oncology Centers
 - 10.2.5.4. Drug Stores
- 10.2.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.2.6.1. Germany
 - 10.2.6.2. France
 - 10.2.6.3. U.K
 - 10.2.6.4. Italy
 - 10.2.6.5. Spain
 - 10.2.6.6. Russia
 - 10.2.6.7. Poland
 - 10.2.6.8. Rest of Europe
- 10.3. Asia-Pacific Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
 - 10.3.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.3.1.1. Drug Therapy
 - 10.3.1.1.1. Gemcitabine Combination Therapy
 - 10.3.1.1.2. 5-fluorouracil Combination Therapy
 - 10.3.1.1.3. Capecitabine Combination Therapy
 - 10.3.1.1.4. Gemcitabine Alone
 - 10.3.1.2. Radiation Therapy
 - 10.3.1.2.1. Brachytherapy
 - 10.3.1.2.2. External Beam Radiation Product (EBRT)

- 10.3.1.3. Surgery
- 10.3.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
- 10.3.3. Intrahepatic Bile Duct Cancer
- 10.3.4. Extrahepatic Bile Duct Cancer
 - 10.3.4.1. Perihilar Bile Duct Cancer
 - 10.3.4.2. Distal Extrahepatic Bile Duct Cancer
- 10.3.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.3.5.1. Hospitals
 - 10.3.5.2. Pharmacies
 - 10.3.5.3. Oncology Centers
 - 10.3.5.4. Drug Stores
- 10.3.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.3.6.1. Japan
 - 10.3.6.2. China
 - 10.3.6.3. India
 - 10.3.6.4. Australia & New Zealand
 - 10.3.6.5. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
 - 10.3.6.6. South Korea
- 10.4. Latin America Companion Animal Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
 - 10.4.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.4.1.1. Drug Therapy
 - 10.4.1.1.1. Gemcitabine Combination Therapy
 - 10.4.1.1.2. 5-fluorouracil Combination Therapy
 - 10.4.1.1.3. Capecitabine Combination Therapy
 - 10.4.1.1.4. Gemcitabine Alone
 - 10.4.1.2. Radiation Therapy
 - 10.4.1.2.1. Brachytherapy
 - 10.4.1.2.2. External Beam Radiation Product (EBRT)
 - 10.4.1.3. Surgery
 - 10.4.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
 - 10.4.3. Intrahepatic Bile Duct Cancer
 - 10.4.4. Extrahepatic Bile Duct Cancer
 - 10.4.4.1. Perihilar Bile Duct Cancer

10.4.4.2. Distal Extrahepatic Bile Duct Cancer

10.4.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.4.5.1. Hospitals

10.4.5.2. Pharmacies

10.4.5.3. Oncology Centers

10.4.5.4. Drug Stores

10.4.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.4.6.1. Brazil

10.4.6.2. Mexico

10.4.6.3. Argentina

10.4.6.4. Venezuela

10.4.6.5. Rest of Latin America

10.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023

10.5.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.1.1. Drug Therapy

10.5.1.1.1. Gemcitabine Combination Therapy

10.5.1.1.2. 5-fluorouracil Combination Therapy

10.5.1.1.3. Capecitabine Combination Therapy

10.5.1.1.4. Gemcitabine Alone

10.5.1.2. Radiation Therapy

10.5.1.2.1. Brachytherapy

10.5.1.2.2. External Beam Radiation Product (EBRT)

10.5.1.3. Surgery

10.5.2. Disease Indication Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.3. Intrahepatic Bile Duct Cancer

10.5.4. Extrahepatic Bile Duct Cancer

10.5.4.1. Perihilar Bile Duct Cancer

10.5.4.2. Distal Extrahepatic Bile Duct Cancer

10.5.5. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.5.1. Hospitals

10.5.5.2. Pharmacies

10.5.5.3. Oncology Centers

10.5.5.4. Drug Stores

10.5.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

10.5.6.1. Gulf Cooperation Council (GCC) Countries

10.5.6.2. Israel

10.5.6.3. South Africa

10.5.6.4. Rest of MEA

11. COMPETITION LANDSCAPE

11.1. Strategic Dashboard of Top Market Players

11.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

11.2.1. Bayer AG (Germany)

11.2.2. Boehringer Ingelheim GmbH (Germany)

11.2.3. Ceva Santé Animale (France)

11.2.4. Eli Lilly and Company (U.S)

11.2.5. Hester biosciences (India)

11.2.6. Merck & Co., Inc. (U.S)

11.2.7. Vétoquinol S.A. (France)

11.2.8. Virbac S.A. (France)

11.2.9. Zoetis Inc. (U.S)

I would like to order

Product name: Global Companion Animal Drugs Market: By Product Type (Antimicrobials, Ectoparasiticides, Endoparasiticides, Endectoparasiticides, Anti-inflammatory Drugs, Anti-Obesity Drugs, Behavioral Products, Biologic Drugs and Others), By Animal Type (Feline, canine, and Equine), By Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals, Veterinary Clinics, and E-Commerce), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G528944CB14EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G528944CB14EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970